3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
3
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
32
Sarcoma
1
Genitourinary
1
Conditions
von Hippel-Lindau Disease
1
Carcinoma, Renal Cell
1
Interventions
Docetaxel
77
Radiotherapy
73
Prednisone
65
Leuprolide
51
Goserelin
49
Gemcitabine
49
Cisplatin
48
bicalutamide
46
enzalutamide
41
Androgen Antagonists
36
pembrolizumab
32
Abiraterone Acetate
30
Mitomycin
29
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
28
Magnetic Resonance Spectroscopy
28
Carboplatin
27
Flutamide
25
Triptorelin Pamoate
23
Sunitinib
23
Nivolumab
23
Radiation
22
apalutamide
21
Doxorubicin
20
darolutamide
18
Gonadotropin-Releasing Hormone
18
cabozantinib
16
abiraterone
16
Specimen Handling
16
Radiosurgery
16
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
palbociclib
×
Genitourinary
×
Clear all
NCT07405164
2026-05-26
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled